Metformin and Glucagon-like peptide-1 (GLP-1) agonists, which have been attracting increasing attention lately, offer promising approaches for reducing the risk of endometrial cancer by impacting molecular and metabolic pathways. The gene discussed is GLP1R; the disease is endometrial cancer.